Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Psoriatic Arthritis
Recruiting3 awardsPhase 3
Frederick, Maryland
This trial is comparing the efficacy, safety, and tolerability of two doses of upadacitinib (15 mg and 30 mg) to placebo for the treatment of psoriatic arthritis. The trial will consist of two periods: Period 1 will compare the three groups of participants and Period 2 will evaluate the long-term safety, tolerability and efficacy of the two doses of upadacitinib.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.